| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC21276 | Seltorexant | A potent, selective, orally active orexin-2 receptor (OX2R) antagonist with pKi of 8.0 and 8.1 for human and rat OX2R, respectively. |
|
| DC21148 | IPI-443 | A potent, selective, orally active p110δ/γ PI3K dual inhibitor with cellular IC50 of 0.29 and 7.1 nM, respectively. |
|
| DC20681 | AS1940477 | A potent, selective, orally active p38α/p38β inhibitor with IC50 of 11.2/36.5 nM respectively, with no effect on p38γ and δ isoforms (IC50>1 uM). |
|
| DC23441 | CS-0777 | A potent, selective, orally active S1P receptor-1 (S1P1) agonist with EC50 of 1.1 nM, 320-fold selectivity over S1P3. |
|
| DC25065 | NIBR 0213 Featured | A potent, selective, orally active S1P1 antagonist with IC50 of 2.5 nM Ca2+ mobilization assays, without activity on S1P2, S1P3 and S1P4 (IC50>10 uM). |
|
| DC21287 | MK-4256 | A potent, selective, orally active somatostatin receptor SSTR3 antagonist with binding Ki of 0.66 nM, >500-fold selectivity over SSTR1/2/4/5. |
|
| DC21295 | MK-1421 | A potent, selective, orally active somatostatin receptor SSTR3 antagonist with binding Ki of 2.3 nM, >2,500-fold selectivity over SSTR1/2/4/5 (IC50>5 uM). |
|
| DC21579 | RO 5073012 | A potent, selective, orally active TAAR1 partial agonist with Ki of 6 nM, EC50 of 23 nM (hTAAR1), 140-fold selectivity over β2 adrenergic receptors. |
|
| DC20654 | AM-0902 Featured | A potent, selective, orally active TRPA1 channel antagonist with IC50 of 71 and 131 nM for rTRPA1 and hTRPA1 in Ca2+ flux assays respectively, without agonist activity (EC50>40 uM). |
|
| DC21179 | JNJ 41876666 | A potent, selective, orally active TRPM8 channel antaognist with IC50 of 0.8 nM, . |
|
| DC23198 | Adomeglivant | A potent, selective, orally active, small-molecule antagonist of human glucagon receptor with Ki of 6.66 nM. |
|
| DC22681 | E 6130 | A potent, selective, orally available CX3C chemokine receptor 1 (CX3CR1) modulator that inhibits the fractalkine-induced chemotaxis of human peripheral blood NK cells with IC50 of 4.9 nM. |
|
| DC23581 | TASP0315003 | A potent, selective, orally available GlyT1 inhibitor with IC50 of 1.6 nM, weakly inhibits rat GlyT2 (IC50=138 nM). |
|
| DC23611 | DCCCyB | A potent, selective, orally available GlyT1 inhibitor with IC50 of 29 nM, demonstrates excellent in vivo occupancy of GlyT1 transporters in vivo.. |
|
| DC23599 | PF-0346275 Featured | PF-0346275 is a potent, selective, orally available GlyT1 inhibitor with Ki of 11.6 nM, without activity against GlyT2 (IC50>10 uM). |
|
| DC23486 | DS-1558 | A potent, selective, orally available GPR40 agonist with EC50 of 3.7 nM. |
|
| DC23300 | T-3256336 | A potent, selective, orally available IAP antagonist with IC50 of 1.3, 2.2 and 200 nM for cIAP-1, cIAP-2 and XIAP, respectively. |
|
| DC24182 | Nilotinib monohydrochloride monohydrate Featured | A potent, selective, orally available inhibitor of both native and mutant Bcr-Abl with IC50 of 20-80 nM. |
|
| DC23925 | Vaniprevir | A potent, selective, orally available inhibitor of HCV NS3/4A protease with Ki of 0.05 and 0.9 nM for GT1b and 2a protease, respectively. |
|
| DC23358 | CD 161 | A potent, selective, orally bioavailable BET bromodomain inhibitor with IC50 of 7.2 and 28.2 nM for BRD4 BD2 and BRD4 BD1, respectively. |
|
| DC21177 | JNJ 39758979 Featured | JNJ-39758979 is a selective, orally active, and high-affinity histamine H4 receptor antagonist with Kis of 12.5, 5.3, and 25 nM for human, mouse, and monkey histamine H4 receptor, respectively. JNJ-39758979 functionally antagonizes histamine-induced cAMP inhibition with a pA2 of 7.9 in transfected cells. JNJ-39758979 shows good anti-inflammatory and antipruritic activity. |
|
| DC24048 | NVP-BKM120 hydrochloride Featured | A potent, selective, orally bioavailable inhibitor of class I PI3K isoforms with IC50 of 52 nM/166 nM/116 nM/262 nM for p110α/β/δ/γ, respectively. |
|
| DC22882 | KRH-3955 | A potent, selective, orally bioavailable inhibitor of CXCR4 that efficiently inhibits SDF-1α binding to CXCR4 with IC50 of 0.61 nM. |
|
| DC24065 | EPZ-011989 trifluoroacetate | A potent, selective, orally bioavailable inhibitor of EZH2 with Ki of < 3 nM. |
|
| DC23552 | AS-2444697 HCl Featured | A potent, selective, orally bioavailable IRAK-4 inhibitor that potently inhibits human and rat IRAK-4 activity with subnanomolar order, >30-fold selectivity over IRAK-1. |
|
| DC22941 | AZD-9056 | A potent, selective, orally bioavailable P2X7 receptor antagonist. |
|
| DC21607 | SB-649868 Featured | SB-649868 is a potent and selective orally active orexin (OX) 1 and OX2 receptor antagonist (pKi =9.4 and 9.5 at the OX1 and OX2 receptor, respectively). |
|
| DC21598 | RWJ-56110 | A potent, selective, peptide-mimetic PAR-1 antagonist with binding IC50 of 0.44 uM, with no effect on PAR-2, PAR-3, or PAR-4. |
|
| DC20691 | ASP 3652 | A potent, selective, peripherally active and orally available FAAH inhibitor for treatment of chronic prostatitis/chronic pelvic pain syndrome.. |
|
| DC23043 | Tpl2-IN-2p | A potent, selective, reversible and ATP-competitive inhibitor of Tpl2 kinase with IC50 of 50 nM. |
|
